Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Celecoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 14/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.98 |
| ▸ | PDPK1 | O15530 | 7/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.98 |
| ▸ | PTGES | O14684 | 1/20 | 0.98 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.98 |
| ▸ | CA12 | O43570 | 1/20 | 0.98 |
| ▸ | PDE5A | O76074 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.98 |
| ▸ | CA1 | P00915 | 1/20 | 0.98 |
| ▸ | CA2 | P00918 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | CA3 | P07451 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Celecoxib SCHEMBL518745 | 0.99 | PTGS2 (0.95) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL516681 | 0.99 | PTGS2 (0.95) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL517497 | 0.99 | PTGS2 (0.95) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL3708 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL3669597 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL9998656 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL6600270 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL3785427 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL5673015 | 0.98 | PDPK1 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL1982868 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100360117-C | Pharmaceutical composition with improved dissolution | TRANSFORM PHARMACEUTICALS INC (US) | 2008-01-09 | — | — | CN | claimed |
| EP-1579198-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | Transform Pharmaceuticals, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2004061433-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | claimed |
| CN-115400145-B | Methods for treating and preventing osteoporosis | 北京罗诺强施医药技术研发中心有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117279681-A | Product delivery device and method | 呼吸解决方案股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4009998-A1 | MICROSPHERE-BASED INJECTIBLE CELECOXIB FORMULATION | Avidence Therapeutics, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-114206366-A | Microsphere-based injectable celecoxib formulations | 艾维登斯医疗公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021026289-A1 | Microsphere-Based Injectible Celecoxib Formulation | AVIDENCE THERAPEUTICS, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| US-8859781-B2 | No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents | Euclises Pharmaceuticals, Inc. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2014012074-A2 | NO-RELEASING NONOATE (NITROGEN-BOUND) SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | Euclises Pharmaceuticals, Inc. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018544-A1 | NO-RELEASING NONOATE(NITROGEN-BOUND)SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | Euclises Pharmaceuticals, Inc. | 2014-01-16 | — | — | US | disclosed |
| CN-1668283-A | Pharmaceutical composition with improved dissolution | TRANSFORM PHARMACEUTICALS INC (US) | 2005-09-14 | — | — | CN | disclosed |
| EP-1515703-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | Transform Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | TRANSFORM PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2004078161-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPTINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078163-A2 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004060347-A2 | PHARMACEUTICAL PROPYLENE GLYCOL SOLVATE COMPOSITIONS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004061433-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004026235-A2 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004000284-A1 | PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | TRANSFORM PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018544-A1 | NO-RELEASING NONOATE(NITROGEN-BOUND)SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | NOS1, NOS2, PTGS1 | PTGS2 10/4885PTGS1 3/4885PDPK1 4793/4885 |
| US-20050025791-A1 | Pharmaceutical compositions with improved dissolution | ABCG2, SI, SLC10A2 | PTGS2 1448/4885PTGS1 1383/4885PDPK1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.